Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome

Table 1

The above values correspond to metabolic and cardiovascular variables.

Variables	W	FFR	SHR	FFHR	FFHR + L
SBP (mmHg)	118 ± 0.8	140 ± 1.8*	172 ± 2.0^*∧	182 ± 1.1^*∧#	165 ± 0.9^*∧†
HOMA (𝜇U/mL insulin × mmol/L glucose)/22.5	4.22 ± 1.1	11.9 ± 1.3*	8.1 ± 2.2*	15.1 ± 2.5*	13.2 ± 2.1*
Fast glucemia (mmol/L)	4.0 ± 1.1	6.8 ± 1.3*	5.2 ± 1.3*	6.92 ± 2.1*	6.5 ± 2.1*
Tryglycerides (mg/dL)	72.5 ± 1.9	109 ± 1.8*	115 ± 2.4*	149 ± 2.2^*∧#	140.9 ± 2.4*
Relative heart weight (mg/100 g corporal weight)	229 ± 2.5	302 ± 2.1*	425 ± 4.4*	475 ± 2.6^*∧#	389 ± 2^*∧†
Vascular NAD(P)H-oxidase activity (cpm/mg)	14.5 ± 3.3	68 ± 1.4*	149 ± 2.6*	366 ± 12^*∧#	197 ± 2.3^*∧#†
TBARS (mmol/L)	39 ± 3.2	118 ± 5.4*	110 ± 3.9*	171 ± 2.6^*∧#	101 ± 2.7^*∧#†
Arterial eNOS activity (dpm·mg P/min)	82.0 ± 2	62 ± 1.5*	81.9 ± 2.6	50.6 ± 1.9^*∧#	71.4 ± 1.1^*∧#†
L/M relationship	13.1 ± 1.4	9.5 ± 1.2*	8.9 ± 2.1*	7.4 ± 1.2^*#	11.5 ± 1.1^*∧#†
PCRus	1.18 ± 0.1	3.2 ± 0.3*	4.5 ± 0.1*	6.7 ± 0.2^*∧#	1.1 ± 0.2^*∧#

* 𝑃<0.001 versus WKY; ^∧𝑃<0.001 versus SHR; ^#𝑃<0.01 versus FFR. ^†versus FFHR.